Description
Description: Sorafenat is an oral medication available in tablet form, containing the active ingredient Sorafenib. It is a multi-kinase inhibitor used in the treatment of various types of cancer, including advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and radioactive iodine-resistant advanced differentiated thyroid carcinoma (DTC).
Indications: Sorafenat is indicated for the treatment of:
- Advanced renal cell carcinoma (RCC), including unresectable, locally advanced, or metastatic RCC.
- Hepatocellular carcinoma (HCC), including patients with unresectable HCC or those who have progressed after receiving prior systemic therapy.
- Radioactive iodine-resistant advanced differentiated thyroid carcinoma (DTC), including locally recurrent or metastatic disease.
Mechanism of Action: Sorafenib inhibits multiple kinases involved in tumor cell proliferation and angiogenesis. It targets the RAF/MEK/ERK signaling pathway, as well as receptors for vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are implicated in tumor growth, angiogenesis, and metastasis.
Dosage and Administration: The dosage of Sorafenat may vary depending on the type of cancer being treated and the patient’s individual response to therapy. It is usually taken orally, with or without food, as directed by a healthcare professional. The tablets should be swallowed whole with a glass of water and not crushed, broken, or chewed.
Precautions and Warnings:
- Sorafenat should be used with caution in patients with a history of cardiac disease, bleeding disorders, hypertension, or liver dysfunction.
- Patients should undergo regular monitoring of blood pressure, liver function tests, and thyroid function tests during treatment with Sorafenat.
- Sorafenat may interact with certain medications, so patients should inform their healthcare provider about all prescription, over-the-counter, and herbal supplements they are taking.
- Women of childbearing potential should use effective contraception during treatment with Sorafenat, as it may cause fetal harm if administered during pregnancy.
Adverse Reactions: Common adverse reactions associated with Sorafenat include diarrhea, fatigue, hand-foot skin reaction (palmar-plantar erythrodysesthesia), rash, hypertension, decreased appetite, nausea, vomiting, abdominal pain, and hair loss. Less common but more serious adverse reactions may include severe bleeding, thrombocytopenia, hepatotoxicity, and cardiac dysfunction.
Storage: Sorafenat should be stored at controlled room temperature away from moisture and heat. The tablets should be kept in their original packaging and stored out of reach of children. Unused or expired tablets should be disposed of properly according to local regulations.
Disclaimer: The information provided here is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult your healthcare provider regarding any questions or concerns you may have about your condition or treatment options.
Reviews
There are no reviews yet.